Clinical trial
Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease
NCT06589804 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- March 27, 2025
- Completion date
- November 30, 2029
- Enrollment
- 158 (estimated)
- Sites
- 200
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic head and neck squamous cell carcinoma, metastatic hypopharyngeal squamous cell carcinoma, metastatic laryngeal squamous cell carcinoma, metastatic oral cavity squamous cell carcinoma, metastatic oropharyngeal squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent neck squamous cell carcinoma of unknown primary, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, refractory head and neck squamous cell carcinoma, refractory hypopharyngeal squamous cell carcinoma, refractory laryngeal squamous cell carcinoma, refractory oral cavity squamous cell carcinoma, refractory oropharyngeal squamous cell carcinoma, stage iv head and neck cutaneous squamous cell carcinoma ajcc v8, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8